Search Within

Wassim Abida

Formats
  1. Meeting Abstract (75)
  2. Journal Article (72)
  3. Editorial (4)
  4. Review (3)
  5. Research Letter (2)
  6. Correspondence (1)
  7. Guidelines (1)
Groups
  1. Department of Medicine (158)
  2. Genitourinary Oncology Service (158)
  3. Solid Tumor Oncology Division (158)
  4. GSK Faculty (72)
  5. Human Oncology and Pathogenesis Program (68)
  6. Sloan Kettering Institute Postdocs (60)

More Groups

People
  1. Howard Scher (68)
  2. Michael Morris (39)
  3. David Solit (36)
  4. Nikolaus Schultz (33)
  5. Anuradha Gopalan (31)
  6. Dana Rathkopf (31)

More People

Years
  1. 2025 (8)
  2. 2024 (10)
  3. 2023 (14)
  4. 2022 (15)
  5. 2021 (19)
  6. 2020 (27)

More Years

Publications
  1. Journal of Clinical Oncology (40)
  2. Clinical Cancer Research (15)
  3. Annals of Oncology (13)
  4. Cancer Research (13)
  5. European Urology (8)
  6. JCO Precision Oncology (4)

More Publications

Publishers
  1. American Society of Clinical Oncology (44)
  2. American Association for Cancer Research (31)
  3. Nature Publishing Group (15)
  4. Oxford University Press (13)
  5. Elsevier Science, Inc. (10)
  6. Nature Research (5)

More Publishers

Results (158)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Synthetic lethal targeting of CDK12-deficient prostate cancer with PARP inhibitors
    Journal Article

    Chou, J.; Robinson, T. M.; Egusa, E. A.; Lodha, R.; Zhang, M.; Badura, M.; Mikayelyan, M.; Delavan, H. M.; Swinderman, J.; Wilson, C.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Automated real-world data integration improves cancer outcome prediction
    Journal Article

    Jee, J.; Fong, C.; Pichotta, K.; Tran, T. N.; Luthra, A.; Waters, M.; Fu, C.; Altoe, M.; Liu, S. Y.; Maron, S. B.; more...
    Nature (2024)

    Fulltext@MSK | Save
  • RAD21 promotes oncogenesis and lethal progression of prostate cancer
    Journal Article

    Su, X. A.; Stopsack, K. H.; Schmidt, D. R.; Ma, D.; Li, Z.; Scheet, P. A.; Penney, K. L.; Lotan, T. L.; Abida, W.; DeArment, E. G.; more...
    Proceedings of the National Academy of Sciences of the United States of America (2024)

    Fulltext@MSK | Save
  • Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer
    Journal Article

    Lenis, A. T.; Ravichandran, V.; Brown, S.; Alam, S. M.; Katims, A.; Truong, H.; Reisz, P. A.; Vasselman, S.; Nweji, B.; Autio, K. A.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Evaluating immune checkpoint blockade in metastatic castration-resistant prostate cancers with deleterious CDK12 alterations in the phase 2 IMPACT trial
    Journal Article

    Nguyen, C. B.; Reimers, M. A.; Perera, C.; Abida, W.; Chou, J.; Feng, F. Y.; Antonarakis, E. S.; McKay, R. R.; Pachynski, R. K.; Zhang, J.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Phase I study of ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer progressing on enzalutamide
    Journal Article

    Abida, W.; Hahn, A. W.; Shore, N.; Agarwal, N.; Sieber, P.; Smith, M. R.; Dorff, T.; Monk, P.; Rettig, M.; Patel, R.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy
    Journal Article

    Walmsley, C. S.; Jonsson, P.; Cheng, M. L.; McBride, S.; Kaeser, C.; Vargas, H. A.; Laudone, V.; Taylor, B. S.; Kappagantula, R.; Baez, P.; more...
    npj Precision Oncology (2024)

    Fulltext@MSK | Save
  • Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)
    Journal Article

    Zhao, J. L.; Antonarakis, E. S.; Cheng, H. H.; George, D. J.; Aggarwal, R.; Riedel, E.; Sumiyoshi, T.; Schonhoft, J. D.; Anderson, A.; Mao, N.; more...
    British Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Impact of PARP inhibitor and platinum therapy on clonal hematopoiesis
    Meeting Abstract

    Baeten, J. T.; Chan, I. C. C.; Moukarzel, L.; Carter, A. C.; Patel, M.; Stopsack, K. H.; Pharoah, P.; Brenton, J.; Li, B. T.; Abida, W.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Evaluating immune-related adverse events using PRO-CTCAE in a phase II study of ipilimumab for hormone-sensitive prostate cancer
    Journal Article

    Vargas P. de Almeida, D.; Anderson, J. M.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Abida, W.; Cohn, E. D.; Baser, R. E.; Scher, H. I.; Autio, K. A.
    Journal of Immunotherapy and Precision Oncology (2023)

    Fulltext@MSK | Save